Global Search | Novartis

Showing 2693 results

Media Release / Apr 23, 2015

Novartis a affiché, au T1[1], une forte progression de ses ventes (tcc), une hausse importante de sa marge (tcc) et une innovation très dynamique; avec un portefeuille désormais mieux ciblé

Ventes, résultat opérationnel core[2] et BPA core (tcc[2]) des activités poursuivies[1] en hausse au T1 Chiffre d'affaires net s'élevant à USD 11,9 milliards (-7%, +3% tcc)]2] Résultat…
Media Release / Apr 23, 2015

Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio

Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)…
Media Release / May 08, 2015

Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC

Zykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib Marketing authorization was based on…
Media Release / Apr 27, 2015

Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL

Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most…
Media Release / May 21, 2015

Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors

Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…
Media Release / May 20, 2015

Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237

QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies…
Media Release / May 27, 2015

Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA

Overall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell…
Media Release / May 31, 2015

Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma

Final analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma Tafinlar and Mekinist in combination…
Media Release / Jun 01, 2015

Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs

In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases[1],[2] Tafinlar (dabrafenib) and…
Media Release / Jun 01, 2015

Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma

Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy[1] Recent milestones for…